Australian Medical Technology Company Opens Minnesota Office
Medtronic veterans Ann Holder and Jack Cosentino join ImpediMed leadership team
MINNEAPOLIS, June 8, 2016 /PRNewswire/ — Australian-based medical technology company ImpediMed Limited (ASX: IPD) announced today the opening of a regional office in Bloomington, Minn., and the addition of two Minnesota medical technology veterans – Ann Holder and Jack Cosentino – to its executive leadership team.
These moves cap an eventful several months for the 55-person company, which develops products using bioimpedance spectroscopy (BIS) to measure, monitor and manage fluid status and body composition. Among ImpediMed’s 2016 developments:
- The U.S. commercial launch of its L-Dex® system to aid in the clinical assessment of secondary unilateral lymphedema of the arm and leg in women and the leg in men;
- The creation of a medical advisory board to counsel on the design of clinical trials for the use of its BIS technology in fluid detection for chronic heart failure patients;
- The completion of a capital raising activity, which raised AU$75.1 million before costs; and
- The signing of a five year, multi-location clinical trial agreement with Rochester, Minn.-based Mayo Clinic.
Growing U.S. and global footprint
ImpediMed’s Bloomington office, located at 2901 Metro Drive, will initially house employees in operations, marketing and business development roles. ImpediMed’s Minnesota office is positioned for growth as it will become the hub for the company’s exploration of new clinical and home-based indications for its BIS technology.
The company’s U.S. headquarters remain in Carlsbad, Calif., with additional employees located at the corporate headquarters in Brisbane, Australia.
“Expanding to the Twin Cities will allow us to take advantage of the diverse and comprehensive medical technology, healthcare delivery and innovation ecosystem thriving across Minnesota,” said Richard Carreon, CEO and Managing Director of ImpediMed. “When you factor in the availability of highly-skilled med-tech talent, quality of life for our employees and proximity to our clinical partners such as the Mayo Clinic, Minnesota is the perfect new home for growing our U.S. operations.”
Senior leadership team adds Minnesota talent
ImpediMed also announced the addition of Minnesota natives Ann Holder and Jack Cosentino, two Medtronic veterans, to ImpediMed’s executive leadership team.
Holder serves as ImpediMed’s Senior Vice President of General Management and Operations. She brings to the role her 13 years of experience at Medtronic, including serving as Executive Director of its Integrated Health Services and Solutions Business.
Before joining Medtronic, Holder served at PepsiCo, M&M/Mars, BoldTech Systems, General Mills and ADC Telecommunications. She is currently a board member for MobCon Digital Health, an annual conference focused on consumer medical devices.
Cosentino, now ImpediMed’s Chief Strategy Officer, brings more than 20 years of experience as an entrepreneur, advisor and leader at medical technology companies and organizations, including Medtronic, MentorMate, MobCon Digital Health and Diversified Medical Corporation. Previously, Cosentino served as Chief Technology Officer for the Medical Alley Association (formerly LifeScience Alley), the 700-member life sciences trade association based in Minneapolis.
Exploring the Potential of Bioimpedance Spectroscopy
Founded in 1999, ImpediMed is the leading developer and manufacturer of fluid measurement and body composition technology. Using bioimpedance spectroscopy (BIS), the proprietary technology sends 256 unique frequencies through the body to assess both intra- and extracellular fluid.
BIS provides a precise, rapid and repeatable snapshot of a person’s lean body mass, fat mass, total body mass, intra- and extracellular fluid and water. By detecting small amounts of fluid change within minutes, the technology can help health care providers better detect and manage chronic disease in patients and gives individuals information to better manage their health conditions or track wellness goals.
Relevant to any market where fluid and body composition are important, there is a wide range of potential clinical and at-home applications for BIS technology, including oncology, cardiology, nephrology, veterinary and wellness. ImpediMed is currently exploring the next generation of products using BIS through strategic clinical partnerships with institutions and companies located in the U.S. and abroad.
ImpediMed currently manufactures products utilizing BIS technology, including the L-Dex® U400 and the SFB7. For more information about ImpediMed products, visit www.impedimed.com or call toll-free 877-247-0111.
Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif., and Bloomington, Minn., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess secondary unilateral lymphedema of the arm and leg in women and the leg in men.
For additional information, visit www.impedimed.com.